toxicities reaching ≥ grade 3 were neutropenia (56.9 %), thrombocytopenia (41.3 %), anemia (31.2 %), and leukopenia (22.0 %). Nonhematologic toxicities observed in more than half of patients included appetite loss (75.2 %), nausea (74.3 %), fatigue (67.9 %), and ALT increased (51.4 %), but the incidence of toxicities of grade 3 or higher was less than 10 %. The majority of adverse events were observed during the initial 4 cycles of pemetrexed and carboplatin combination therapy. Common toxicities ≥ grade 3 observed in the maintenance period were similar to those observed during the initial combination treatment period, including neutropenia (40.0 %), thrombocytopenia (16.7 %), leukopenia (11.7 %), and anemia (13.3 %). Newly emerged or deteriorated toxicities during maintenance periods were rarely observed. No treatment-related deaths were reported in this study.
